Concentration‐Based Short‐Course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (iCRS) for Advanced Ovarian Cancer: Final Analysis of Overall Survival in a Phase 2 Trial
Konzentrationsbasierte Kurzzeit-HIPEC bei Intervall-Zytoreduktionschirurgie (iCRS) bei fortgeschrittenem Ovarialkarzinom: Endanalyse des Gesamtüberlebens in einer Phase-2-Studie
Journal of Surgical Oncology · 02.11.2026
DOI: 10.1002/jso.70444 ↗Auf einen Blick
In einer Phase-2-Studie bei fortgeschrittenem Ovarialkarzinom war das Langzeit-Gesamtüberleben unter konzentrationsbasierter Kurzzeit-HIPEC günstig. Die Autor:innen berichten zudem eine Machbarkeit und Sicherheit des Regimes.
Fragestellung
Welche Langzeit-Gesamtüberlebensdaten ergeben sich für eine konzentrationsbasierte Kurzzeit-HIPEC bei iCRS beim fortgeschrittenen Ovarialkarzinom?
Methode
Multizentrische, einarmige Phase-2-Studie bei Patient:innen mit fortgeschrittenem Ovarialkarzinom nach NACT und iCRS; HIPEC 30 min bei 41°C–43°C mit Cisplatin allein oder plus Doxorubicin.
Ergebnisse
15 Patient:innen; medianes Follow-up 110,6 Monate (95 %-KI 85,2–nicht erreicht). Medianes Gesamtüberleben 83,9 Monate (95 %-KI 31,3–nicht erreicht); 5-Jahres-Überleben 53,3 % (95 %-KI 33,2–85,6).
Schlussfolgerung der Autor:innen
Konzentrationsbasierte Kurzzeit-HIPEC ist laut Autor:innen ein machbares und sicheres Regime bei Ovarialkarzinom und mit günstigem Langzeit-Gesamtüberleben verbunden.
Kernaussagen
- 15 Patient:innen mit fortgeschrittenem Ovarialkarzinom wurden eingeschlossen
- Medianes Gesamtüberleben: 83,9 Monate
- 5-Jahres-Überleben: 53,3 %
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 02.11.2026. Verfasst von Thales Paulo Batista und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, UFPE - Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The optimal regimen for Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) remains controversial. We aim to present long‐term overall survival results from our phase 2 trial evaluating a concentration‐based short‐course regimen for ovarian cancer at the time of interval CytoReductive Surgery (iCRS).
Methods
This was a multicenter, single‐arm, phase 2 trial including patients with advanced ovarian cancer undergoing iCRS after neoadjuvant chemotherapy (NACT). HIPEC was administered via the closed‐abdomen technique for 30 min at 41°C–43°C, comprising the use of cisplatin (25 mg/L of perfusate/m 2 , total limit 240 mg) alone, or in combination with doxorubicin (15 mg/L, total limit 90 mg).
Results
Between February 2015 and July 2019, fifteen patients were enrolled and followed for a median of 110.6 months (95% CI, 85.2 – not reached). Median overall survival was 83.9 months (95% CI, 31.3 – not reached), with a 5‐year survival rate of 53.3% (95% CI, 33.2–85.6) and a restricted mean survival time truncated at 5 years of 45·6 months (95% CI, 37.2–54.0). At the time of this analysis, 13.3% were alive without disease, 13.3% remained on systemic therapy, and 73.3% had died.
Conclusion
Concentration‐based short‐course HIPEC is a feasible and safe regimen for ovarian cancer patients. This approach is associated with favorable long‐term overall survival, highlighting the need for head‐to‐head comparisons of different HIPEC regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, UFPE - Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil.
- Department of Surgery/Oncology, IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil.
- Department of Surgery/Oncology, IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Department of Gynecology, HCP - Hospital de Câncer de Pernambuco, Recife, Pernambuco, Brazil.
- Department of Clinical Oncology, IMIP - Instituto de Medicina Integral Professor Fernando Figueira, and Department of Clinical Oncology, HCP - Hospital de Câncer de Pernambuco, Recife, Pernambuco, Brazil.
- Department of Gynecology, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
- Department of Gynecology, IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo, São Paulo, Brazil.
ORCID-Profile: Thales Paulo Batista, Ana Beatriz Diniz de Barros, Vandré Cabral Gomes Carneiro, Rodrigo Tancredi, Levon Badiglian-Filho, Ronaldo Lúcio Rangel Costa, André Lopes, Bruno José de Queiroz Sarmento, Cristiano Souza Leão
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Batista, T. P., de Barros, A. B. D., Carneiro, V. C. G., Tancredi, R., Badiglian-Filho, L., Costa, R. L. R., Lopes, A., Sarmento, B. J. Q., & Leão, C. S. (2026). Concentration‐Based Short‐Course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (iCRS) for Advanced Ovarian Cancer: Final Analysis of Overall Survival in a Phase 2 Trial. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70444
Vancouver
Batista TP, de Barros ABD, Carneiro VCG, Tancredi R, Badiglian-Filho L, Costa RLR, et al. Concentration‐Based Short‐Course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (iCRS) for Advanced Ovarian Cancer: Final Analysis of Overall Survival in a Phase 2 Trial. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70444
BibTeX
@article{Batista2026,
author = {Batista, Thales Paulo and de Barros, Ana Beatriz Diniz and Carneiro, Vandré Cabral Gomes and Tancredi, Rodrigo and Badiglian-Filho, Levon and Costa, Ronaldo Lúcio Rangel and Lopes, André and Sarmento, Bruno José de Queiroz and Leão, Cristiano Souza},
title = {Concentration‐Based Short‐Course Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at Interval Cytoreductive Surgery (iCRS) for Advanced Ovarian Cancer: Final Analysis of Overall Survival in a Phase 2 Trial},
journal = {Journal of Surgical Oncology},
year = {2026},
doi = {10.1002/jso.70444}
}
EUVIMED